Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $3 Million Public Offering of Common Stock of Cocrystal Pharma, Inc.
Press Release – New York, NY – November 4, 2019 – Sichenzia Ross Ference LLP announced today that it has represented Aegis Capital Corp. as sole book runner in the underwritten public offering of 3,529,412 shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) common stock, at a price of $0.85 per share for gross proceeds of approximately $3.0 million. Cocrystal is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio and Avital Perlman, counsel Jeff Cahlon and associate Grant Levine.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents HiVentures Zrt., a Hungarian Venture Capital Company, in Private Placement of Series A Preferred Stock of ActiveGraf - January 16, 2020
- Trusts and Estates Attorney - January 13, 2020
- Sichenzia Ross Ference LLP Represents A.G.P./Alliance Global Partners as Sole Placement Agent in $3M Registered Direct Offering of Cellect Biotechnology Ltd. - January 10, 2020